[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] #  @Mike182035 Mike Wilk Mike Wilk posts on X about novartis, faster, $bns, settings the most. They currently have XX followers and XXX posts still getting attention that total XXX engagements in the last XX hours. ### Engagements: XXX [#](/creator/twitter::1649320141505609729/interactions)  - X Week XXXXX -XXXX% - X Month XXXXXX +987% - X Months XXXXXX -XX% - X Year XXXXXXX +421% ### Mentions: X [#](/creator/twitter::1649320141505609729/posts_active)  - X Week XX -XXXX% - X Month XX +900% - X Months XX -XX% - X Year XXX +600% ### Followers: XX [#](/creator/twitter::1649320141505609729/followers)  - X Week XX +7.90% - X Month XX +12% - X Months XX +20% ### CreatorRank: XXXXXXXXX [#](/creator/twitter::1649320141505609729/influencer_rank)  ### Social Influence [#](/creator/twitter::1649320141505609729/influence) --- **Social category influence** [stocks](/list/stocks) [finance](/list/finance) **Social topic influence** [novartis](/topic/novartis) #27, [faster](/topic/faster) #1745, [$bns](/topic/$bns), [settings](/topic/settings) **Top assets mentioned** [Novartis AG (NVS)](/topic/novartis) [Bank of Nova Scotia (BNS)](/topic/$bns) ### Top Social Posts [#](/creator/twitter::1649320141505609729/posts) --- Top posts by engagements in the last XX hours "#AVCT Not allowed to reply Jason But tbh I think practically all serious pharma are contenders And I am being serious too" [X Link](https://x.com/Mike182035/status/1980967079055409193) [@Mike182035](/creator/x/Mike182035) 2025-10-22T11:58Z XX followers, 2915 engagements "#AVCT This is actually also part of the arguement for BP to partner rather than early takeover The former a cheaper method of backing both horses" [X Link](https://x.com/Mike182035/status/1980905318562574547) [@Mike182035](/creator/x/Mike182035) 2025-10-22T07:53Z XX followers, 1411 engagements "#AVCT There is very little doubt that all relevant Pharma are aware of Avacta - it's just a non topic She's an ex Avacta employee I believe" [X Link](https://x.com/Mike182035/status/1980975279993389523) [@Mike182035](/creator/x/Mike182035) 2025-10-22T12:31Z XX followers, 2193 engagements "#AVCT 2/n "4. Illustrative ExampleImagine AVA6207 in pancreatic cancer (KRAS-driven mito-addicted):Primary Warhead: Exatecan (topo I inhibitor) causes DNA breaks killing proliferative cells. Mito-Warhead: Venetoclax (BCL-2 inhibitor) hits mitochond."" [X Link](https://x.com/Mike182035/status/1981429999996482036) [@Mike182035](/creator/x/Mike182035) 2025-10-23T18:38Z XX followers, XXX engagements "#AVCT Don't you mean $bns question Ben It's a guess but I have a suspicion this development will shortly be shown to be funded" [X Link](https://x.com/Mike182035/status/1977702794661412914) [@Mike182035](/creator/x/Mike182035) 2025-10-13T11:47Z XX followers, 1255 engagements "#AVCT 3/n ".mitochondria releasing cytochrome c and collapsing m. This:Sensitizes: Lowers apoptosis threshold so exatecans DNA damage triggers faster cell death. Blocks Resistance: Prevents OXPHOS/BCL-2 upregulation in hypoxic stem cells which would otherwise." "" [X Link](https://x.com/Mike182035/status/1981431236120985968) [@Mike182035](/creator/x/Mike182035) 2025-10-23T18:43Z XX followers, XXX engagements "#AVCT ".Verdict: The triple-warhead construct is the stronger contender for CSC-driven TNBC leveraging mito-specificity to tackle relapse (40-50% vs. XX% CSC kill) but its longer timeline (9-11 vs. 8-9 years) and tox risks make the dual-warhead a safer faster bet for ."" [X Link](https://x.com/Mike182035/status/1981450579667792226) [@Mike182035](/creator/x/Mike182035) 2025-10-23T20:00Z XX followers, XXX engagements "#AVCT ".market entry. Triples edge shines in refractory settings aligning with Avactas 2025 vision (AVA6207s CSC focus) and . mito-expertise. Monitor Avactas October XX 2025 investor update for triple-warhead hints." Usual AI caveats - garbage in garbage out" [X Link](https://x.com/Mike182035/status/1981451208914035112) [@Mike182035](/creator/x/Mike182035) 2025-10-23T20:02Z XX followers, XXX engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@Mike182035 Mike Wilk
Mike Wilk posts on X about novartis, faster, $bns, settings the most. They currently have XX followers and XXX posts still getting attention that total XXX engagements in the last XX hours.
Engagements: XXX #
- X Week XXXXX -XXXX%
- X Month XXXXXX +987%
- X Months XXXXXX -XX%
- X Year XXXXXXX +421%
Mentions: X #
- X Week XX -XXXX%
- X Month XX +900%
- X Months XX -XX%
- X Year XXX +600%
Followers: XX #
- X Week XX +7.90%
- X Month XX +12%
- X Months XX +20%
CreatorRank: XXXXXXXXX #
Social Influence #
Social category influence stocks finance
Social topic influence novartis #27, faster #1745, $bns, settings
Top assets mentioned Novartis AG (NVS) Bank of Nova Scotia (BNS)
Top Social Posts #
Top posts by engagements in the last XX hours
"#AVCT Not allowed to reply Jason But tbh I think practically all serious pharma are contenders And I am being serious too"
X Link @Mike182035 2025-10-22T11:58Z XX followers, 2915 engagements
"#AVCT This is actually also part of the arguement for BP to partner rather than early takeover The former a cheaper method of backing both horses"
X Link @Mike182035 2025-10-22T07:53Z XX followers, 1411 engagements
"#AVCT There is very little doubt that all relevant Pharma are aware of Avacta - it's just a non topic She's an ex Avacta employee I believe"
X Link @Mike182035 2025-10-22T12:31Z XX followers, 2193 engagements
"#AVCT 2/n "4. Illustrative ExampleImagine AVA6207 in pancreatic cancer (KRAS-driven mito-addicted):Primary Warhead: Exatecan (topo I inhibitor) causes DNA breaks killing proliferative cells. Mito-Warhead: Venetoclax (BCL-2 inhibitor) hits mitochond.""
X Link @Mike182035 2025-10-23T18:38Z XX followers, XXX engagements
"#AVCT Don't you mean $bns question Ben It's a guess but I have a suspicion this development will shortly be shown to be funded"
X Link @Mike182035 2025-10-13T11:47Z XX followers, 1255 engagements
"#AVCT 3/n ".mitochondria releasing cytochrome c and collapsing m. This:Sensitizes: Lowers apoptosis threshold so exatecans DNA damage triggers faster cell death. Blocks Resistance: Prevents OXPHOS/BCL-2 upregulation in hypoxic stem cells which would otherwise." ""
X Link @Mike182035 2025-10-23T18:43Z XX followers, XXX engagements
"#AVCT ".Verdict: The triple-warhead construct is the stronger contender for CSC-driven TNBC leveraging mito-specificity to tackle relapse (40-50% vs. XX% CSC kill) but its longer timeline (9-11 vs. 8-9 years) and tox risks make the dual-warhead a safer faster bet for .""
X Link @Mike182035 2025-10-23T20:00Z XX followers, XXX engagements
"#AVCT ".market entry. Triples edge shines in refractory settings aligning with Avactas 2025 vision (AVA6207s CSC focus) and . mito-expertise. Monitor Avactas October XX 2025 investor update for triple-warhead hints." Usual AI caveats - garbage in garbage out"
X Link @Mike182035 2025-10-23T20:02Z XX followers, XXX engagements